@Article{,
AUTHOR = {Tu D. Dan, Laura Doyle, Amar J. Raval, Andrew Pridjian, Leonard G. Gomella, Robert B. Den},
TITLE = {Dosing, administration, and safety of  radium-223: How I do it},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {23},
YEAR = {2016},
NUMBER = {3},
PAGES = {8301--8305},
URL = {http://www.techscience.com/CJU/v23n3/61160},
ISSN = {1488-5581},
ABSTRACT = {Radium-223 dichloride is a first-in-class bone-directed 
radiopharmaceutical that has been shown to prolong 
survival in men with metastatic castrate resistant prostate 
cancer (mCRPC). Unlike other radiopharmaceuticals, 
radium-223 uniquely uses alpha-emission to deliver 
high intensity, short range cytoxic treatments resulting 
in minimal myelosuppression. Following the results of 
the ALSYMPCA trial, radium-223 (Xofigo) was FDA 
approved in the United States in May 2013 and approved 
by Health Canada in December 2013 for the treatment 
of mCRPC with symptomatic bone metastases and no 
visceral disease. This “How I do it” article describes the 
background of radium 223 as well as the methods and 
techniques that our institution uses for safe and effective 
administration and notes the subtle differences when 
administering the drug in Canada.},
DOI = {}
}